Hospitals resume Sarepta’s gene therapy, but brace for coverage hurdles

For weeks, Katie Yoder was glued to headlines tracking the FDA’s back-and-forth over Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy. When the company agreed to stop shipping the gene therapy on July 21, treatment ...